MX2007008722A - Elementos de aglutinacion especifica para el factor de crecimiento nervioso. - Google Patents

Elementos de aglutinacion especifica para el factor de crecimiento nervioso.

Info

Publication number
MX2007008722A
MX2007008722A MX2007008722A MX2007008722A MX2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A
Authority
MX
Mexico
Prior art keywords
ngf
antibody molecules
specific binding
binding members
psoriasis
Prior art date
Application number
MX2007008722A
Other languages
English (en)
Inventor
Ruth Franks
Andrew Grier Buchanan
Albert George Thom
Fraser Ewing Welsh
Philip Antony Bland-Ward
Matthew Alexander Sleeman
Carl Anthony Matthews
Celia Patricia Hart
Jon Hawkinson
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of MX2007008722A publication Critical patent/MX2007008722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invencion se refiere a elementos de aglutinacion especifica para el factor del crecimiento nervioso (NGF) (por sus siglas en ingles), en particular a moleculas de anticuerpos anti-NGF, especialmente moleculas de anticuerpos humanos, y especialmente aquellas que neutralizan la actividad de NGF. Los metodos para utilizar las moleculas de anticuerpos anti-NGF en el diagnostico o tratamiento de los trastornos relacionados con NGF, incluyendo el dolor, asma, enfermedad pulmonar obstructiva cronica, fibrosis pulmonar, otras enfermedades de inflamacion de las vias respiratorias, neuropatia diabetica, arritmias cardiacas, VIH, artritis, psoriasis y cancer.
MX2007008722A 2005-01-24 2006-01-24 Elementos de aglutinacion especifica para el factor de crecimiento nervioso. MX2007008722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64558705P 2005-01-24 2005-01-24
PCT/GB2006/000238 WO2006077441A1 (en) 2005-01-24 2006-01-24 Specific binding members for ngf

Publications (1)

Publication Number Publication Date
MX2007008722A true MX2007008722A (es) 2008-02-15

Family

ID=36088563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008722A MX2007008722A (es) 2005-01-24 2006-01-24 Elementos de aglutinacion especifica para el factor de crecimiento nervioso.

Country Status (18)

Country Link
US (2) US9315571B2 (es)
EP (2) EP2298345A3 (es)
JP (1) JP5096167B2 (es)
KR (1) KR101298383B1 (es)
CN (1) CN101107268B (es)
AU (1) AU2006207338B2 (es)
BR (1) BRPI0606933B8 (es)
CA (1) CA2595800C (es)
ES (1) ES2435691T3 (es)
HK (1) HK1105208A1 (es)
IL (1) IL183752A (es)
MX (1) MX2007008722A (es)
NO (1) NO343064B1 (es)
NZ (1) NZ556157A (es)
PT (1) PT1846451E (es)
RU (1) RU2406728C2 (es)
WO (1) WO2006077441A1 (es)
ZA (1) ZA200705754B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
BRPI0407375A (pt) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
GEP20104887B (en) 2003-07-15 2010-02-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
HUE037549T2 (hu) 2004-04-07 2018-09-28 Rinat Neuroscience Corp Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7488630B2 (en) 2007-03-06 2009-02-10 International Business Machines Corporation Method for preparing 2-dimensional semiconductor devices for integration in a third dimension
CA2695997C (en) * 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
EP2231179A2 (en) * 2007-12-20 2010-09-29 Cytos Biotechnology AG Ngf conjugates and uses thereof
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
EP2431463A4 (en) * 2009-05-13 2012-12-26 Shionogi & Co TESTS FOR VISCERAL ADIPOSITAS AND ITS USE
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
PT3333188T (pt) 2010-08-19 2022-03-28 Zoetis Belgium S A Anticorpos de anti-ngf e a sua utilização
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
MX351273B (es) 2011-08-11 2017-10-06 Astellas Pharma Inc Nuevo anticuerpo anti-ngf humano.
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
RS60156B1 (sr) * 2014-02-02 2020-05-29 Medimmune Ltd Himerni protein sačinjen od ngf antagonist domena i tnfa antagonist domena
WO2016190263A1 (ja) * 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
US20210147529A1 (en) 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
EP4217388A1 (en) 2020-09-28 2023-08-02 MedImmune Limited Compounds and methods for treating pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559834A1 (en) 1990-11-30 1993-09-15 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
WO2001027279A1 (en) 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
AU770115B2 (en) * 1999-12-13 2004-02-12 Cambridge Antibody Technology Limited Brain specific binding members
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2002308722B2 (en) * 2001-05-30 2007-05-17 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003102136A2 (en) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
GEP20104887B (en) 2003-07-15 2010-02-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Also Published As

Publication number Publication date
WO2006077441A1 (en) 2006-07-27
CN101107268B (zh) 2012-06-27
EP1846451B1 (en) 2013-05-15
NO20074266L (no) 2007-10-23
CN101107268A (zh) 2008-01-16
US20080107658A1 (en) 2008-05-08
BRPI0606933A2 (pt) 2009-12-01
BRPI0606933B1 (pt) 2019-12-10
PT1846451E (pt) 2013-08-28
KR101298383B1 (ko) 2013-08-20
US9315571B2 (en) 2016-04-19
CA2595800A1 (en) 2006-07-27
AU2006207338B2 (en) 2011-12-08
US9701746B2 (en) 2017-07-11
IL183752A (en) 2013-12-31
EP2298345A3 (en) 2012-03-21
KR20070100330A (ko) 2007-10-10
JP2008527989A (ja) 2008-07-31
WO2006077441A8 (en) 2008-04-10
ES2435691T3 (es) 2013-12-23
RU2406728C2 (ru) 2010-12-20
HK1105208A1 (en) 2008-02-06
IL183752A0 (en) 2007-09-20
ZA200705754B (en) 2008-06-25
RU2007132020A (ru) 2009-02-27
CA2595800C (en) 2014-07-08
BRPI0606933B8 (pt) 2021-05-25
EP2298345A2 (en) 2011-03-23
NZ556157A (en) 2009-09-25
EP1846451A1 (en) 2007-10-24
US20160297878A1 (en) 2016-10-13
AU2006207338A1 (en) 2006-07-27
JP5096167B2 (ja) 2012-12-12
NO343064B1 (no) 2018-10-22

Similar Documents

Publication Publication Date Title
MX2007008722A (es) Elementos de aglutinacion especifica para el factor de crecimiento nervioso.
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Rothenberg Humanized anti-IL-5 antibody therapy
WO2005051366A3 (en) Diaryl urea derivatives in the treatment of protein kinase dependent diseases
WO2008065378A3 (en) Binding members for interleukin-6
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
HK1095355A1 (en) Regulation of a kinase, 'regulated in copd kinase' (rc kinase)
Buesa et al. Iadademstat shows efficacy in elderly AML patients in combination with azacitidine. ALICE trial
Laurencin et al. Fracture repair: challenges and opportunities
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
Midence et al. Women’s risk factor control by cardiac rehabilitation program model: a randomized controlled trial
Souza et al. RESPIRATORY MUSCLE TRAINING IN PEOPLE WITH COPD: A SYSTEMATIZED REVIEW
Mukhopadhyay et al. The Role of Iron Chelation Activity of Wheat Grass Juice in Blood Transfusion Requirement of Intermediate Thalassaemia.
Ferro et al. INFLUENCE OF PHOTOBIOMODULATION ON CELL VIABILITY OF MULTIPOTENT MESENCHYMAL STEM CELLS FROM ADIPOSE TISSUE IN VITRO
Hush Tens of unknown value in the treatment of chronic low back pain
Kozhevnikov et al. Retrospective analysis of intraarticular effectiveness of triamcinolone acetonide in treatment of oligoarticular juvenile arthritis in children
Zanin-Zhorov et al. A selective and potent rock 2 inhibitor (KD025) decreases human STAT3-dependent IL-21 and IL-17 production and experimental chronic graft-versus-host disease (cGVHD)
Sowter et al. Fatigue, quality of life, and physical fitness following an exercise intervention in survivors of multiple myeloma: a randomised controlled trial using a Zelen design
Alape et al. Expiratory Central Airway Collapse and Medical Management: Outcome Analysis
Frangoul et al. Differing Definitions of Vaso-Occlusion in Clinical Studies of Sickle Cell Disease Can Result in Differing Outcomes
Henshaw NP-109: Improving long-term quality of life for patients living with multiple myeloma: a service evaluation
Hillengass et al. NP-110: Physical activity in multiple myeloma: a review of the literature
Yang et al. Trends in Acupuncture Therapy in Cardiovascular Disease: A Bibliometric Analysis.

Legal Events

Date Code Title Description
FG Grant or registration